Trial Profile
A Phase II, Randomized, Double Blind, Placebo Controlled, Three-way Crossover Study to Assess the Bronchodilator Effect of RPL554 Administered in Addition to Open Label Tiotropium/Olodaterol in Patients With COPD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2020
Price :
$35
*
At a glance
- Drugs Ensifentrine (Primary) ; Olodaterol/tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Verona Pharma
- 20 May 2020 Results of post-hoc analyses evaluating patients with >100mL improvement in FEV1,presented at the 116th International Conference of the American Thoracic Society
- 01 May 2020 Results published in the Verona Pharma Media Release.
- 01 May 2020 According to a Verona Pharma media release, data from this study is published as an abstract on the ATS website and today in the peer reviewed publication, American Journal of Respiratory and Critical Care Medicine.